ATAI Life Sciences

Yahoo Finance • 4 days ago

H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion

Atai Beckley NV (NASDAQ:ATAI) ranks among the most oversold biotech stocks to invest in. H.C. Wainwright reaffirmed its Buy rating and $15 price target for Atai Beckley NV (NASDAQ:ATAI) on November 14 following the company’s third-quarter... Full story

Yahoo Finance • 11 days ago

Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato

Atai Beckley NV (NASDAQ:ATAI) is a must-buy penny stock to buy now. On November 12, TD Cowen’s Ritu Baral reaffirmed a Buy rating on Atai Beckley NV (NASDAQ:ATAI), pointing to encouraging clinical progress and solid financial footing. Posi... Full story

Yahoo Finance • 17 days ago

ATAI Life Sciences GAAP EPS of -$0.28 misses by $0.17, revenue of $0.75M beats by $0.69M

* ATAI Life Sciences press release [https://seekingalpha.com/pr/20303399-ataibeckley-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights] (ATAI [https://seekingalpha.com/symbol/ATAI]): Q3 GAAP EPS of -$0.28 misse... Full story

Yahoo Finance • 17 days ago

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extensi... Full story

Yahoo Finance • last month

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on O... Full story

Yahoo Finance • last month

Cathie Wood's Ark Invest weekly recap: buys BABA, BIDU; sheds PLTR, SHOP and SOFI

Cathie Wood’s ARK ETFs have made several significant trades during the last week, adjusting their portfolios across various sectors. TOP STOCKS BOUGHT: Ark Funds continues to build a position in Alibaba (BABA [https://seekingalpha.com/sy... Full story

Yahoo Finance • last month

Atai Life Sciences Prices Underwritten Offering Of About 23.73 Mln Shares At $5.48/shr

(RTTNews) - atai Life Sciences (ATAI) announced that it has priced its registered underwritten offering of about 23.73 million common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up t... Full story

Yahoo Finance • last month

atai Life Sciences Announces Pricing of Public Offering of Common Shares

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announc... Full story

Yahoo Finance • last month

atai Life Sciences, Beckley Psytech get FDA breakthrough therapy status for BPL-003

[Micro Dosing with Psilocybin Magic Mushrooms] microgen/iStock via Getty Images * atai Life Sciences (NASDAQ:ATAI [https://seekingalpha.com/symbol/ATAI]) and Beckley Psytech have received Breakthrough Therapy designation from the FDA fo... Full story

Yahoo Finance • last month

atai Life Sciences Announces Proposed Public Offering of Common Shares

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announc... Full story

Yahoo Finance • last month

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depressionFDA designation follows previously announced Phase 2b topline d... Full story

Yahoo Finance • 2 months ago

Psychedelic stocks gain after positive remarks from GOP Senator in North Carolina

[Magic Mushroom stock images] Betka82/iStock via Getty Images Companies focused on psychedelic medicines traded higher on Tuesday after Marijuana Moment reported Bob Brinson, a Republican state senator in North Carolina, as saying that hi... Full story

Yahoo Finance • 2 months ago

Cathie Wood's Ark Invest weekly recap: sheds shares in Palantir Technologies, Shopify, Roblox

Wall Street's mood soured last week after U.S. President Donald Trump threatened higher tariffs to China, saying it had "become very hostile" sending letters to other countries wanting to "impose export controls." Major averages plummeted... Full story

Yahoo Finance • 2 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, w... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best healthcare penny stocks to buy now. On September 15, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $15 price target. The positive stance follows a meeting between the... Full story

Yahoo Finance • 2 months ago

atai Life Sciences Awarded Grant from the National Institutes of Health

NEW YORK and AMSTERDAM, Sept. 18, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform... Full story

Yahoo Finance • 3 months ago

atai Life Sciences to Participate in September Investor Conferences

NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform... Full story

Yahoo Finance • 4 months ago

Cathie Wood Loads Up Millions on Google, AMD in Bold ARK Shift

July 29 - Cathie Wood's ARK ETFs tweaked their portfolios Monday, rotating into tech and biotech names as they fine?tune sector exposure. The biggest addition came in ARKW, where ARK bought 181,640 shares of Alphabet (NASDAQ:GOOG) for rou... Full story

Yahoo Finance • 4 months ago

Cathie Wood's ARK buys AMD and Alphabet stock, sells Coinbase and Robinhood

Cathie Wood’s ARK ETFs have made significant moves in the stock market on Monday, July 28, 2025, with a series of buys and sells that investors are keenly observing. The trades indicate a strategic adjustment of the funds’ holdings, with a... Full story

Yahoo Finance • 4 months ago

AMD and ServiceNow Highlight Monday's Market Cap Stock Movers

Monday’s market has seen notable movements among a range of stocks, with significant activity in both the mega-cap and large-cap categories. While stocks such as Adv Micro Device (NASDAQ:AMD) and ServiceNow Inc (NYSE:NOW) have experience... Full story